Straits Times Index
3,093.45 -4.80 (-0.15%) Nikkei
27,753.37 -182.25 (-0.65%) Hang Seng
23,742.31 +83.39 (+0.35%) FTSE 100
7,168.68 +109.23 (+1.55%) BTC-USD
56,819.57 -314.68 (-0.55%) CMC Crypto 200
1,445.96 -23.12 (-1.57%)
Organon & Co. (OGN)
After hours:
| Previous close | 29.23 |
| Open | 29.57 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 28.57 - 29.96 |
| 52-week range | 27.25 - 38.75 |
| Volume | |
| Avg. volume | 1,899,652 |
| Market cap | 7.284B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 4.81 |
| EPS (TTM) | 5.97 |
| Earnings date | 11 Nov 2021 |
| Forward dividend & yield | 1.12 (3.83%) |
| Ex-dividend date | 19 Nov 2021 |
| 1y target est | 40.50 |
- Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2021
JERSEY CITY, N.J., November 11, 2021--Organon (NYSE: OGN) (the "company"), today announced its results for the third quarter and year to date ended September 30, 2021.
- Business Wire
Organon to Acquire Forendo Pharma
JERSEY CITY, N.J. & TURKU, Finland, November 11, 2021--Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral
- CNW Group
NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary
Organon (NYSE: OGN) is pleased to announce NEXPLANON® (etonogestrel extended-release subdermal implant) public listing in Quebec under the Régie de l'assurance maladie du Québec (RAMQ) as of November 10. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 Quebec is the fifth jurisdiction to list NEXPLANON® on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.
